Inflamación en las espondiloartritis: aspectos diferenciales

Crespillo, Juan de Dios Cañete

doi:10.1016/s1699-258x(07)73635-5

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spondyloarthritis (SpA) comprises a group of rheumatic inflammatory chronic diseases that share clinical, radiographic, and immunogenic characteristics [ 1 , 2 ]. This condition mainly affects males under 45 years of age and includes the following subtypes: ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PsA), inflammatory bowel disease associated with arthropathy, and undifferentiated spondyloarthritis (uSpA) [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Symptoms and Elevated Levels of Anti-Saccharomyces cerevisiae Antibodies Are Associated with Higher Disease Activity in Colombian Patients with Spondyloarthritis

Romero-Sánchez

Bautista-Molano

Parra

et al. 2017

International Journal of Rheumatology

View full text Add to dashboard Cite

Background Spondyloarthritis (SpA) is a group of articular inflammatory rheumatic diseases that their gastrointestinal manifestations are around 10% of their extra-articular symptoms, supporting that the inflammatory response of the intestinal mucosa could be associated with the clinical status. Objectives To investigate the association between gastrointestinal symptoms and autoantibodies and disease activity between SpA patients, healthy subjects (HS), and patients with inflammatory bowel disease (IBD). Methods 102 SpA patients, 29 IBD patients, and 117 HS were included. Autoantibodies as ASCA, ANCA, anti-tTG, anti-DGP, ANA, and IgA were measured. The patients were assessed to evaluate clinical and gastrointestinal symptoms. An association analysis was performed using Chi square test and a logistic regression. Results Significant differences were found for ASCA levels in SpA (28.2%) compared to IBD (14.2%) and HS (6.0%) (p = 0.029), as well as for ANAS in SpA (49.5%) and IBD (37.9%) (p < 0.001) and abdominal pain (p = 0.012) between SpA (54.3%) and IBD (27.5%). Significant associations were found between BASDAI > 4 and gastrointestinal symptoms (p < 0.05) and IgA (p = 0.007). The association for abdominal bloating was maintained (OR: 3.93, CI-95%, 1.14–13.56; p = 0.030). Conclusions Gastrointestinal symptoms, ASCA, ANAS, and IgA levels were associated with high disease activity in SpA compared with IBD and HS.

show abstract

Section: Introductionmentioning

confidence: 99%